Biological rationale for patient-specific treatment of breast cancer. Analysis of new data for breast cancer

Abstract

Breast cancer is the most common malignancy in females. More than 1.7 million of cases are detected annually worldwide. The incidence of breast cancer in Russia has increased by 64 % over the last 20 years. There was a 1.43-fold increase in the prevalence of breast cancer (from 297 to 457cases per 100,000) between 2005 and 2017. A total of59,538 new cases were registered in the Russian Federation in 2012. In Russia, breast cancer is the most common malignancy among women aged 40—85years and the second most common cancer among women aged 15—39 (after cervical cancer). The disease is primarily detected in women aged between 40 and 54 years (29.5 %). More than 66,000 of new cases of breast cancer are registered in the Russian Federation annually. In 2017, there were 70,293 new cases of breast cancer; of them, 49,134 patients (69.9 %) hade stage I—II breast cancer. There was a 0.02 % increase in the proportion of new cases of stage I—II breast cancer in 2016—2017. For this reason, it is important to study in depth the markers of breast cancer used in everyday practice in order to personalize the treatment of patients with breast cancer.

Keywords

• breast cancer
• breast cancer markers
• patient-specific treatment